Ignite Creation Date:
2025-12-24 @ 2:49 PM
Ignite Modification Date:
2026-02-11 @ 2:15 AM
Study NCT ID:
NCT02431559
Status:
COMPLETED
Last Update Posted:
2022-10-10
First Post:
2015-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LUD2014-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None